Preventing a Decline in Physical Function in Older Androgen-Deprived Men with Structured Exercise Training
通过结构化运动训练预防雄激素缺乏的老年男性身体机能下降
基本信息
- 批准号:10090555
- 负责人:
- 金额:$ 23.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-01 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:Activities of Daily LivingAdverse effectsAgeAggressive courseAgonistAmericanAndrogen SuppressionAndrogensAttentionAttenuatedBody CompositionBody WeightCastrationClinicalControl GroupsCross-Sectional StudiesDual-Energy X-Ray AbsorptiometryEnrollmentEnsureEquilibriumEtiologyExerciseExercise TherapyExhibitsFatigueFatty acid glycerol estersFunctional disorderGoalsGonadotropin Hormone Releasing HormoneHealthHormonesInterventionIntervention TrialLaboratoriesLeadLower ExtremityMaintenanceMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMedical CastrationMetastatic Prostate CancerMethodsMuscleMuscular AtrophyOrchiectomyOrganOutcomePatientsPerformancePhenotypePhysical FunctionPhysical PerformancePreventionProstateProstate Cancer therapyProstatectomyPublic HealthQuality of lifeQuestionnairesRandomizedRandomized Controlled TrialsRegimenReportingRoleSF-36ScanningSerumStandardizationStructureTestosteroneThinnessTimeTissuesTrainingUnited StatesUpper ExtremityVisitandrogen deprivation therapyandrogen sensitiveattentional controlcomparative efficacydesignefficacy evaluationexercise interventionexercise physiologistexercise regimenexercise trainingexperiencefall riskfallsflexibilityfrailtyhealth related quality of lifehigh riskimprovedinstrumentlean body massmenmuscle formmuscle strengtholder menpatient populationpreservationpreventprimary outcomeprospectiverandomized trialrecruitreduced muscle strengthresilienceresistance exercisetherapy design
项目摘要
PROJECT SUMMARY/ABSTRACT
The overall goal of this proposal is to determine the efficacy of resistance exercise training in preventing the
decline in physical function in men with prostate cancer (PCa) undergoing androgen deprivation therapy (ADT).
As testosterone has a central role in the stimulation of prostate tissue, ADT is the cornerstone of treatment in
men with high grade and metastatic PCa. ADT results in castrate levels of serum testosterone and this
profound androgen deficiency leads to a reduction in lean mass and an increase in fat mass. These
perturbations in body composition follow an aggressive course in these men as loss of lean mass is evident
within 6-8 weeks of starting ADT. These unfavorable changes in body composition result in decreased muscle
strength, which in turn, results in a decline in physical function. These adverse effects have serious
consequences as men on ADT have a higher risk of frailty and falls compared with men with PCa who do not
undergo ADT and are only treated with prostatectomy. Despite declines in these functional tasks that are
patient-important and critical to maintenance of independence, not a single randomized trial has been
performed in these men to evaluate the efficacy of a structured exercise regimen in preventing decline in
physical function. A handful of previous studies had only enrolled men who were already receiving ADT and
had already encountered significant muscle atrophy; therefore, as expected, no meaningful improvements in
physical function were seen. Furthermore, previous studies did not provide equal attention to control groups.
We propose a randomized, controlled, parallel group trial to determine the efficacy of 6-months of structured
resistance exercise training in preventing the decline in physical function (assessed by loaded stair
climbing power) in men age 60 years and older who are about to begin ADT for PCa. We will also provide
equal attention to the control group using structured, patient-important, but outcome innocuous interventions
(flexibility and balance exercises). We will also evaluate the efficacy of exercise training on muscle mass
(DEXA scan), muscle strength (1RM method), QOL (SF-36 questionnaire) and fatigue (FACIT-F
questionnaire). The findings of this trial will lay the groundwork for definitive intervention trials to prevent hard
outcomes of frailty and falls in men undergoing ADT. As frailty imposes a significant public health burden and
is associated with diminished functional capacity and resilience, the proposed trial is likely to have a substantial
clinical impact in the overall health and independence of this patient population.
项目概要/摘要
该提案的总体目标是确定阻力运动训练在预防
接受雄激素剥夺疗法(ADT)的前列腺癌(PCa)男性身体机能下降。
由于睾酮在刺激前列腺组织方面发挥着核心作用,因此 ADT 是治疗的基石。
患有高级别和转移性前列腺癌的男性。 ADT 导致血清睾酮的去势水平,这
严重的雄激素缺乏会导致瘦体重减少和脂肪量增加。这些
这些男性的身体成分紊乱伴随着攻击性过程,因为瘦体重明显减少
开始 ADT 后 6-8 周内。这些身体成分的不利变化会导致肌肉减少
力量,进而导致身体机能下降。这些不良影响严重
后果是,与未接受 ADT 治疗的前列腺癌患者相比,接受 ADT 治疗的男性出现虚弱和跌倒的风险更高
接受 ADT 并且仅接受前列腺切除术治疗。尽管这些功能性任务有所下降
患者对维持独立性至关重要且至关重要,但尚未有任何一项随机试验
对这些男性进行了评估,以评估结构化锻炼方案在预防功能衰退方面的功效。
身体机能。之前的一些研究只招募了已经接受 ADT 的男性,
已经出现明显的肌肉萎缩;因此,正如预期的那样,没有任何有意义的改进
身体机能都看到了。此外,之前的研究并没有对对照组给予同等的关注。
我们提出了一项随机、对照、平行组试验来确定 6 个月结构化治疗的有效性
防止身体机能下降的抗阻运动训练(通过负重楼梯评估)
攀爬能力)适用于即将开始 ADT 治疗 PCa 的 60 岁及以上男性。我们还将提供
使用结构化的、对患者重要但结果无害的干预措施对对照组给予同等关注
(灵活性和平衡练习)。我们还将评估运动训练对肌肉质量的功效
(DEXA 扫描)、肌力(1RM 方法)、QOL(SF-36 问卷)和疲劳(FACIT-F
问卷)。该试验的结果将为明确的干预试验奠定基础,以预防硬性病的发生。
接受 ADT 的男性虚弱和跌倒的结果。由于虚弱给公共健康带来了巨大的负担
与功能能力和恢复能力下降有关,拟议的试验可能会产生大量的影响
对该患者群体的整体健康和独立性的临床影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shehzad Basaria其他文献
Shehzad Basaria的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shehzad Basaria', 18)}}的其他基金
Mentoring in Endocrine and Cardiometabolic Abnormalities in Cancer and Aging
癌症和衰老中内分泌和心脏代谢异常的指导
- 批准号:
10469444 - 财政年份:2021
- 资助金额:
$ 23.03万 - 项目类别:
Exploring the Role of Testosterone as a Novel Anti-Nociceptive Agent in Women with Chronic Pain and Opioid Use
探索睾酮作为新型抗伤害剂对患有慢性疼痛和阿片类药物使用的女性的作用
- 批准号:
10413965 - 财政年份:2021
- 资助金额:
$ 23.03万 - 项目类别:
Mentoring in Endocrine and Cardiometabolic Abnormalities in Cancer and Aging
癌症和衰老中内分泌和心脏代谢异常的指导
- 批准号:
10300180 - 财政年份:2021
- 资助金额:
$ 23.03万 - 项目类别:
Exploring the Role of Testosterone as a Novel Anti-Nociceptive Agent in Women with Chronic Pain and Opioid Use
探索睾酮作为新型抗伤害剂对患有慢性疼痛和阿片类药物使用的女性的作用
- 批准号:
10189910 - 财政年份:2021
- 资助金额:
$ 23.03万 - 项目类别:
Mentoring in Endocrine and Cardiometabolic Abnormalities in Cancer and Aging
癌症和衰老中内分泌和心脏代谢异常的指导
- 批准号:
10652585 - 财政年份:2021
- 资助金额:
$ 23.03万 - 项目类别:
Androgen Replacement to Improve Patient-Important Outcomes in Men with Opioid-Induced Hypogonadism
雄激素替代疗法可改善阿片类药物引起的性腺功能减退症男性患者的重要预后
- 批准号:
10266840 - 财政年份:2020
- 资助金额:
$ 23.03万 - 项目类别:
Androgen Replacement to Improve Patient-Important Outcomes in Men with Opioid-Induced Hypogonadism
雄激素替代疗法可改善阿片类药物引起的性腺功能减退症男性患者的重要预后
- 批准号:
10118343 - 财政年份:2020
- 资助金额:
$ 23.03万 - 项目类别:
Androgen Replacement to Improve Patient-Important Outcomes in Men with Opioid-Induced Hypogonadism
雄激素替代疗法可改善阿片类药物引起的性腺功能减退症男性患者的重要预后
- 批准号:
10426373 - 财政年份:2020
- 资助金额:
$ 23.03万 - 项目类别:
Improving Patient-Important Outcomes with Testosterone Replacement in Hypogonadal Men with a Prior History of Cancer
通过睾酮替代疗法改善有癌症病史的性腺功能减退男性的患者重要结果
- 批准号:
10223238 - 财政年份:2019
- 资助金额:
$ 23.03万 - 项目类别:
Improving cancer-related fatigue, sexual dysfunction and quality of life in older men with cancer and androgen deficiency
改善患有癌症和雄激素缺乏的老年男性与癌症相关的疲劳、性功能障碍和生活质量
- 批准号:
9982751 - 财政年份:2019
- 资助金额:
$ 23.03万 - 项目类别:
相似国自然基金
儿童药品不良反应主动监测中时序处理策略的方法学研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于真实世界医疗大数据的中西药联用严重不良反应监测与评价关键方法研究
- 批准号:82274368
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于隐狄利克雷分配模型的心血管系统药物不良反应主动监测研究
- 批准号:82273739
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于真实世界数据的创新药品上市后严重罕见不良反应评价关键方法研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
OR10G7错义突变激活NLRP3炎症小体致伊马替尼严重皮肤不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
Midcareer award in aging-related subspecialty research
与衰老相关的专业研究中的职业生涯中期奖
- 批准号:
10570687 - 财政年份:2023
- 资助金额:
$ 23.03万 - 项目类别:
Aortic stiffness, wave reflection, and cerebrovascular flow pulsatility: relations with brain small vessel disease and cognitive function in a middle-aged cohort
主动脉僵硬度、波反射和脑血管血流搏动:与中年队列中脑小血管疾病和认知功能的关系
- 批准号:
10662819 - 财政年份:2023
- 资助金额:
$ 23.03万 - 项目类别:
Stress and Human Stem/Progenitor Cells: Biobehavioral Mechanisms
压力与人类干/祖细胞:生物行为机制
- 批准号:
10522469 - 财政年份:2022
- 资助金额:
$ 23.03万 - 项目类别:
Stress and Human Stem/Progenitor Cells: Biobehavioral Mechanisms
压力与人类干/祖细胞:生物行为机制
- 批准号:
10684115 - 财政年份:2022
- 资助金额:
$ 23.03万 - 项目类别:
Sickle Cell Disease and Cardiovascular Risk- Red Cell Exchange SCD-CARRE
镰状细胞病和心血管风险 - 红细胞交换 SCD-CARRE
- 批准号:
10653703 - 财政年份:2022
- 资助金额:
$ 23.03万 - 项目类别: